What Do International Pharmacoeconomic Guidelines Say about Economic Data Transferability?  by Barbieri, Marco et al.
What Do International Pharmacoeconomic Guidelines Say
about Economic DataTransferability?vhe_771 1028..1037
Marco Barbieri, PhD,1 Michael Drummond, PhD,2 Frans Rutten, PhD,MSc,3 John Cook, PhD,4 Henry A. Glick, PhD,5
Joanna Lis, PhD,Msc,6 Shelby D. Reed, PhD, RPh,7 Mark Sculpher, PhD,1 Johan L. Severens, PhD,8
on behalf of the ISPOR Good Research Practices Economic DataTransferability Task Force
1i3 Innovus, Uxbridge, Middlesex, UK; 2Centre for Health Economics, University ofYork, York, UK; 3Erasmus University Medical Centre,
Rotterdam,The Netherlands; 4Merck & Co. Inc., NorthWales, PA, USA; 5University of Pennsylvania, Philadelphia, PA, USA; 6Sanoﬁ-Aventis
Group Poland, Warsaw, Poland; 7Duke Clinical Research Institute, Durham,NC, USA; 8CAPHRI/Maastricht University and Maastricht
University Medical Center, Maastricht,The Netherlands
ABSTRACT
Objectives: The objectives of this article were to assess the positions of the
various national pharmacoeconomic guidelines on the transferability (or
lack of transferability) of clinical and economic data and to review the
methods suggested in the guidelines for addressing issues of transferability.
Methods: A review of existing national pharmacoeconomic guidelines
was conducted to assess recommendations on the transferability of clinical
and economic data, whether there are important differences between
countries, and whether common methodologies have been suggested to
address key transferability issues. Pharmacoeconomic guidelines were ini-
tially identiﬁed through the ISPOR Web site. In addition, those national
guidelines not included in the ISPOR Web site, but known to us, were also
considered.
Results: Across 27 sets of guidelines, baseline risk and unit costs were
uniformly considered to be of low transferability, while treatment effect
was classiﬁed as highly transferable. Results were more variable for
resource use and utilities, which were considered to have low transferabil-
ity in 63% and 45% of cases, respectively. There were some differences
between older and more recent guidelines in the treatment of transferabil-
ity issues.
Conclusions: A growing number of jurisdictions are using guidelines for
the economic evaluation of pharmaceuticals. The recommendations in
existing guidelines regarding the transferability of clinical and economic
data are quite diverse. There is a case for standardization in dealing with
transferability issues. One important step would be to update guidelines
more frequently.
Keywords: clinical trials, cost-effectiveness analysis, decision-analytic
modeling, multivariate regression.
Introduction
Many jurisdictions now request economic evaluations as part of
their decision-making procedures for the pricing and/or reim-
bursement of pharmaceuticals and other health technologies. In
most cases, these requests are supported by national guidelines
on the conduct of economic evaluation. As more and more
jurisdictions request economic studies, the burden on health tech-
nology manufacturers and researchers increases, particularly
when the various national guidelines insist on the presentation of
local data, or the use of speciﬁc methods.
The data requirements for a full economic evaluation of two
or more treatment alternatives are quite diverse, including infor-
mation on baseline risk, treatment effect, resource utilization,
health state preference values (utilities), and costs. Therefore, it is
common for some of the data to be from outside the jurisdiction
for which the evaluation is being performed. This is especially
true of the clinical data, which may be drawn from large con-
trolled trials conducted in a wide range of settings, which may or
may not include patients from the jurisdiction of interest.
There are a number of reasons why clinical outcomes, health
state preference values, resource utilization or costs might vary
from location to location [1]. Thus, it is to be expected that
decision-makers will prefer economic evaluations that are appli-
cable in their own jurisdiction. As far as individual categories of
data may not be relevant to other jurisdictions, this will affect the
generalizability, or transferability of the study results as a whole.
Studies may be considered generalizable if they can be applied to
a range of jurisdictions without any adjustment needed for inter-
pretation. In addition, some studies may be transferable if they
can be adapted to apply to other settings. Finally, some may be so
speciﬁc to a given jurisdiction that they are simply not transfer-
able to any other jurisdiction.
The objectives of this article were to assess positions of the
various national guidelines on transferability (or lack of trans-
ferability) of clinical and economic data, to review the methods
suggested in the guidelines for addressing issues of transferability
of data, and to discuss these in the context of the recommenda-
tions of the recent ISPOR Good Practices Task Force on Eco-
nomic Data Transferability [2].
Methods
A review of all the existing national pharmacoeconomic guide-
lines was conducted to assess which recommendations are given
on the transferability of clinical and economic data, whether
there are important differences between countries, or whether
common methodologies have been suggested to address key
transferability issues.
Pharmacoeconomic guidelines were identiﬁed through the
ISPOR Web site http://www.ispor.org/PEguidelines/index.asp.
We considered this the most valuable and comprehensive source
because guidelines are selected for inclusion in the database on
the basis of contacts with experts from approximately 60 coun-
tries from around the world and annually updated, or whenever
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new guidelines are issued. Guidelines available in English, or in
languages that could be understood by at least one author of this
article (e.g., Spanish, French, Portuguese, Italian, Polish, Dutch,
German), were included in the analysis. (This resulted in the
exclusion of two sets of Asian guidelines that were only available
in the local language.) Each guideline was reviewed in detail to
extract recommendations on the need for local data, or com-
ments on the degree of data transferability, for the following ﬁve
main categories of data:
1. baseline risk
2. treatment effect
3. health state preference values (utilities)
4. resource utilization
5. unit costs (prices)
It is probably best to think of the transferability of data as
being represented by a spectrum, with “generalizable” being at
one end and “not transferable” at the other. Within the spectrum,
hard-and-fast judgments about transferability are hard to make
and the views taken in individual countries’ guidelines are often
tempered by views about the ease of ﬁnding relevant local data in
situations where data from outside the jurisdiction of interest are
deemed to be unacceptable. Nevertheless, to characterize the
similarities, or differences, between different countries’ guide-
lines, recommendations on transferability/lack of transferability
of data and/or study results were summarized as having high or
low transferability:
1. High transferability. Elements of economic evaluations
from other locations are considered to have high transfer-
ability when they can be used in local analyses. For
example, this could be the case for an estimate of absolute
treatment effect obtained from a multinational randomized
controlled trial (RCT) conducted in patient populations
considered similar to those in the jurisdiction of interest. An
estimate of relative treatment effect could also be considered
to have high transferability even if derived from an RCT
conducted in a patient population potentially different from
the population in the jurisdiction of interest, as long as it is
applied to a local estimate of baseline risk to make it rel-
evant to the new jurisdiction. More generally, this category
includes all cases where the guidelines accept the use of data
elements from other countries without major restrictions.
2. Low transferability. This category includes all cases where
data from other jurisdictions are not accepted, or cases in
which the guidelines are very restrictive in the use of those
data. For example, it includes situations where data from
other locations are not accepted under any circumstances
(e.g., estimates of unit costs from a jurisdiction known to
differ in price levels from the jurisdiction of interest). It also
includes situations where there is a strong preference for
local data, but where the guidelines state that estimates
from other locations could be assessed for relevance to the
local context. This could be the case for resource-use data
obtained from studies conducted in other jurisdictions with
different treatment patterns, where an expert panel might
review the data, with a view to providing estimates more
relevant to the local context should this be considered
necessary.
This classiﬁcation can be considered in relation to the algo-
rithm described in the report of the ISPOR Task Force on Eco-
nomic Data Transferability [3]. In this algorithm, after it has
been determined that the data in an existing study are sound and
relevant to the current decision problem, a decision has to be
made about whether the patient populations and resource-use
practice patterns in the study are similar to those in the jurisdic-
tion of interest. If not, further analysis will be required, either
through the statistical analysis of individual patient data, or
through decision-analytic modeling (See Fig. 1).
A secondary aim of our reviewwas to identify which methods,
if any, existing pharmacoeconomic guidelines suggest for address-
ing the issue of transferability of data elements between locations.
Consistent with those explored in the Task Force report, we
considered whether the guidelines recommended any analytical
methods to overcome the problems of dealing with data obtained
from other locations in two different analytic contexts:
1. when the economic evaluation was based on individual-
patient data from a single clinical trial; and
2. when the economic evaluation was based on a decision
analytic model.
Results
Thirty-seven guidelines for economic evaluation were identiﬁed
and reviewed. These were issued in the following 27 countries:
Australia, Austria, the Baltic countries (Latvia, Lithuania and
Estonia), Belgium, Brazil, Canada, Cuba, England and Wales,
Finland, France, Germany, Hungary, Ireland, Israel, Italy,
Mexico, The Netherlands, New Zealand, Norway, Poland, Por-
tugal, Russian Federation, Scotland, Spain, Sweden, Switzerland,
and the United States. All these guidelines were obtained from
the ISPOR Web site, except for Poland, for which an updated
version of the guidelines was known to one of the authors.
Twenty-three guidelines were available in English versions, 3 in
Spanish (Spain, Cuba, Mexico) and one in Portuguese (Brazil).
There were seven countries (Belgium, Canada, England and
Wales, Germany, Poland, Spain and the US) where more than one
set of guidelines was identiﬁed. In these cases, we selected and
extracted information from the set of guidelines that was consid-
ered to be the “ofﬁcial version” for manufacturer submissions
(i.e., guidelines for the Drug Reimbursement Committee in
Belgium, National Institute for Health and Clinical Excellence
(NICE) for England andWales, Institute forQuality andEfﬁciency
in Health Care (IQWiG) for Germany and Guidelines for Con-
ducting Health Quality Assessment (HTA) in Poland), or the most
recent (i.e., Lopez-Bastida et al. for Spain). In the case of Canada,
the guidelines issued by the Common Drug Review (CDR) and
Canadian Agency for Drugs and Technologies in Health
(CADTH) were assessed together because the ofﬁcial guidelines
produced by the CDR often refer to those of CADTH for meth-
odological issues. Finally, for the United States, we selected the
AMCP Format because, although it is not in any sense “ofﬁcial,”
it is currently themost widely followed set of guidelines. Although
we restricted the analysis to one set of guidelines per country, we
also checked any other sets of guidelines for these countries to
identify whether any alternative method to deal with the issue of
transferability of data was recommended.
Appendix 1 (found at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i8_Drummond.asp) provides a full list
of guidelines, together with the most recent year of publication in
those cases where updated versions of previous guidelines had
been produced. Based on the inclusion and exclusion criteria
outlined above, our analysis was based on 27 sets of guidelines.
Transferability of Key Data Inputs
The results on the degree of transferability of the ﬁve key data
inputs (baseline risk, treatment effect, health state utilities,
resource use, and unit costs) are presented in Figure 2. Table 1
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gives the same results stratiﬁed by country. A more detailed
presentation of the recommendations made by each guideline on
each data input is available in Appendix 2 at: http://
www.ispor.org/Publications/value/ViHsupplementary/ViH13i8_
Drummond.asp.
Although there was great variation in the level of detail and
signiﬁcance given to the issue of transferability of data, it
appears that there is general agreement among guidelines on
which data are more or less likely to be transferable between
jurisdictions.
Figure 1 Steps for determining appropriate methods for adjusting cost-effectiveness (CE) information.
0 5 10 15 20 25 30
Unit costs
Resource use
Health utilities
Treatment effect
Baseline risk
High transferability
Low transferability
Not stated
     Number of Guidelines with Recommendation 
Figure 2 Level of Transferability of Data Elements (As reﬂected in National Guidelines). Note: The “not stated” category includes both cases in which no
details were given and cases in which the item of interest was not discussed separately from another item. For baseline risk and treatment effect no details were
given in 4 cases, while in 12 cases they were discussed together. For health utilities, no information was given in 16 cases. Resource use and unit costs were discussed
together in 5 cases, while no details were given in 2 cases for unit costs and in 6 cases for resource use.
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Clinical data: baseline risk and relative treatment effect. The
ISPOR Good Practices Task Force Report made a distinction
between estimates of relative treatment effect, which are often
considered to be more generalizable, and estimates of baseline
event rates, which are often considered to be more jurisdiction-
speciﬁc. Approximately half of the guidelines make an explicit
distinction between baseline risk and treatment effect for clinical
data, while the other half do not clearly delineate between these
two components. Four sets of guidelines do not make any state-
ment on transferability of clinical data.
In all cases where baseline risk and treatment effect are
discussed separately, the answer to the question of whether
these data are transferable among locations is clear: baseline
risk is considered to have low transferability (11 cases),
while treatment effect is generally considered to have high
transferability (11 cases). Even in cases of high transferability,
the guidelines often suggest giving attention to the applicability
of the trials to the local context (e.g., differences between
trial patients and local population, adequacy of comparators,
etc.). Indeed, it is possible that, even within a given jurisdiction,
the treatment effect from a trial may not be generalizable
because of differences between the selected nature of the
patients enrolled in studies for drug licensing and the patients
treated in routine practice. This, however, is an issue that
goes well beyond that of transferability of studies across
jurisdictions.
The main reason for using country-speciﬁc data for baseline
measures of clinical events is the potential difference in epide-
miological data between locations where the use of estimates
from other settings could be misleading. In a few cases (New
Zealand and Australia), the pharmacoeconomic guidelines
suggest that only when these estimates are not available for the
country of interest, the absolute risk of clinical events or other
epidemiological estimates could be taken from similar locations,
as long as these can be made relevant to the country where the
analysis is performed and validated (on the basis, for example, of
expert opinion).
The guidelines often suggest that treatment effect (e.g., rela-
tive risk of an intervention with respect to a comparator) is
transferable between locations. In this case, the use of high
quality data (for example, from systematic reviews or large,
randomized clinical trials) is recognized as a key factor, and more
important than the use of local data. Therefore, a recommenda-
tion made by some guidelines (New Zealand and AMCP in the
United States) is to obtain treatment effect from multinational
clinical trials and then to superimpose this on estimates of base-
line probabilities of survival, or other endpoints obtained from
local population-based sources.
Nevertheless, in some cases, the guidelines highlight the need
for potential adjustment of the results obtained from a clinical
trial (even when extracted as a relative risk reduction) to the local
context, given the potential differences between settings (mainly
in terms of population characteristics). In fact, in some circum-
stances, differences in patient characteristics might have an
impact not only on baseline risk but also on treatment effect (e.g.,
treatment effect might depend on duration of disease, severity of
patient population, number of previous drugs received, etc.). All
of these factors could potentially differ between locations,
between trials and regular practice, and within a given trial. In
the latter case, this would suggest the use of methods to deal with
heterogeneity, rather than being an issue of data transferability.
The key issue is whether the trial shows that there is a difference
in treatment effect between patient subgroups.
Those guidelines that do not make an explicit split between
baseline risk and treatment effect generally suggest that clinical
data are transferable, but with adaptation to the local context for
differences in some factors. Among these factors, epidemiological
data, patient characteristics, comparators used, and clinical prac-
tice are often mentioned.
Health state preference values (health state utilities). More than
60% of the guidelines (16 out of 27) do not make any recom-
mendation on the transferability between locations of utility
estimates. In the remaining cases, there is great variability, with
six guidelines suggesting that utility estimates are highly trans-
ferable and ﬁve suggesting that they have low transferability.
It appears, however, that these differences are mainly caused
by different degrees of ﬂexibility in the various national guide-
lines for accepting data from other locations, based on the
availability of these data in the country of interest. For
example, the Canadian guidelines state that utility values
obtained from other countries are, in general, not transferable
to the Canadian setting because of cultural differences. Also, in
England and Wales, the NICE guidelines state that utility values
should be measured in patients using a generic and validated
classiﬁcation system for which reliable UK population prefer-
ence values are available, although they will consider estimates
from other sources. A similar recommendation is made in New
Zealand.
In many cases, utility weights are not readily available for the
country of interest; it is often recognized that utilities need to be
obtained from other countries. This is particularly true for small
countries (e.g., Hungary, Ireland, and Belgium) or countries
where the use of economic evaluation might be less developed
(e.g., Brazil). In these cases, great attention is given to the need
for transparency, in that the data sources and instruments used
should be stated, together with a discussion of their applicability
to the country of interest. Finally, sensitivity analyses are often
recommended when utility values are obtained from studies per-
formed in other settings.
Resource use and unit costs. Resource use and unit costs were
addressed separately in 22 of the 27 guidelines, but 6 of these 22
guidelines did not provide any explicit information on the degree
of transferability of resource use. The majority of the remaining
guidelines recommend obtaining resource use from the local
setting, arguing that estimates from elsewhere low transferability
has. Differences in clinical practices, payment systems, incentives,
and the opportunity to redeploy resources are often mentioned as
the main reasons for variability in resource use between loca-
tions. These guidelines suggest that it is fundamental to use local
data for resource consumption and estimates obtained from
other locations are often not considered as an appropriate and
valid source.
As for utility weights, however, small countries appear more
ﬂexible in accepting data from other settings and in six cases
estimates of resource use are seen as having high transferability.
This happens, for example, in the case of Hungary, Poland, or
Israel, where there might be greater difﬁculties in collecting
local data or obtaining these data from local published studies.
In general, these guidelines state that if resource utilization esti-
mates are obtained from published studies performed in other
locations, these should be adapted to the country of interest,
for example by means of expert opinion. Also, they suggest
that any method used to adjust resource use from other loca-
tions to the country of interest should be explained and
justiﬁed.
As regards unit costs, all the 22 guidelines that analyzed
these data separately from resource use agree that they must
be jurisdiction-speciﬁc because of differences in relative and
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absolute prices between countries. Some guidelines also provide
sources for unit costs (e.g., an ofﬁcial list). Most guidelines
recommend presenting quantities of resource use separately from
unit costs to increase the transparency of the analysis.
Transferability of Key Data Inputs: Additional Analyses
In addition, it was hypothesized that the degree of ﬂexibility in
accepting data from other jurisdictions might be dependent on
two factors: 1) the year in which a guideline was issued, and 2)
the level of development of economic evaluation methods in the
country of interest.
To assess whether these two factors have an impact on the
results of the study, we conducted two additional analyses. First,
we divided the 27 guidelines into two groups based on publi-
cation date. It was found that 14 guidelines were issued before
2005, while 13 guidelines were published from 2005 to date.
Thus, 2005 was chosen as reference year because it split the
guidelines in two almost equal groups. Second, we divided the
guidelines into two groups based on the degree of development
of economic evaluation in the jurisdiction concerned. To iden-
tify countries that were mature in their experience of economic
evaluation, two of the authors (MB and MD) independently
made the assessment and then discussed the ﬁndings to reach a
consensus.
Transferability of data by year of publication of the guidelines.
Although the sample of guidelines was relatively small to draw
ﬁrm conclusions, two important differences were found between
guidelines published before and after year 2005. First, “older”
guidelines provide much fewer details on transferability issues.
For example, nothing was stated on transferability of utility
weights in 10 cases out of 14 for older guidelines versus 6 of 13
for the newer guidelines. Similarly, no information was given on
transferability of resource use in ﬁve cases for guidelines pub-
lished before 2005, while this happened only in one case for
newer guidelines. In addition, baseline risk/treatment effect or
resource use/unit costs were discussed separately more often in
newer guidelines as compared with the older guidelines. Speciﬁ-
cally, baseline risk and treatment effect were not presented sepa-
rately in seven cases for older guidelines versus ﬁve cases for
newer guidelines, while resource use and unit costs were not
presented separately in four cases for older guidelines versus only
one case for newer guidelines.
The second element that distinguishes the two sets of guide-
lines is the extent to which data from other jurisdictions are
accepted in the country of interest. In general, the older guide-
lines are more ﬂexible in accepting data from other countries. In
fact, while for some data inputs the two sets of guidelines
provide very clear and similar results (baseline risk and unit
costs are generally considered to be not transferable, while
treatment effect is considered to have a high degree of transfer-
ability), different results were found for resource use and health
utilities. In the case of resources used (when presented sepa-
rately from unit costs), the older guidelines suggest that they are
highly transferable in 3 cases out of 5, while only in 3 cases out
of 11 for the newer guidelines. Similarly, utility weights are
viewed as being highly transferable in three cases out of four for
older guidelines, while only in two cases out of nine in newer
guidelines (in all the remaining cases nothing was stated). These
ﬁndings suggest that more attention has been given to transfer-
ability issues in recent years and that updated versions of old
guidelines might be more restrictive in accepting data from
other jurisdictions.
Transferability by degree of development of economic evalu-
ation. On the basis of the independent assessment of two
authors of the article, the following two groups of countries were
as follows:
1. more mature countries (Australia, Belgium, Canada,
England/Wales, Finland, France, Germany, Italy, the Neth-
erlands, New Zealand, Portugal, Scotland, Spain, Sweden,
USA)
2. less mature countries (Austria, Baltic countries, Brazil,
Cuba, Hungary, Ireland, Israel, Mexico, Norway, Poland,
Russian Federation, Switzerland).
The results of this analysis are quite similar to those of the
comparison between older and newer guidelines First, less
mature countries appear to provide fewer details on speciﬁc data
items, although this difference is not as great as in the case of
older versus newer guidelines. For example, baseline risk and
treatment effect are presented separately in 11 cases out of 15 in
more mature countries, while only in 4 cases of 12 in less mature
countries. On the other hand, the number of “not stated” items
is similar between the two groups.
Second, as in the case of older guidelines, less mature coun-
tries appear to be more ﬂexible in accepting data from other
jurisdictions. This is evident in the case of resource use, which
was considered not transferable in 8 cases out of 10 in more the
mature countries, while considered to be highly transferable in
four out of six cases in the less mature countries. This might
reﬂect the fact in mature countries the availability of local eco-
nomic data are likely to be higher than in less mature countries.
Nevertheless, we did not ﬁnd clear differences for all the other
data items (e.g., baseline risk, treatment effect, utilities, and unit
costs).
The Application of Guidelines in Practice
Although pharmacoeconomic guidelines often make clear state-
ments about transferability (or lack of transferability) of data, it
is interesting to assess whether published economic evaluations
and industry submissions to speciﬁc agencies follow the recom-
mendations in the jurisdiction concerned. It is clearly unrealistic
to analyse all studies or reports produced in the 27 countries
considered, so we focused on the speciﬁc case of NICE for
England and Wales. NICE was chosen because of the high trans-
parency of the appraisal process and the wide availability of
documentation on the NICE Web site. All published technology
appraisals on the NICEWeb site from July 2008 to October 2009
were considered because this time period followed the introduc-
tion of the latest methods guidelines in June 2008. Two data
inputs were considered on the grounds that there is still some
debate about whether they are transferable or not:
1. baseline risk;
2. health utilities.
NICE’s methods guidelines recommend that baseline risk has
“to be relevant to UK practice and patients, and to compare all
relevant treatment options for the relevant patient groups.” Nev-
ertheless, it is added that “evidence on effectiveness might come
from outside the UK health care system . . . . Despite such weak-
nesses in the evidence base, decisions still have to be made about
the use of technologies. Therefore, analyses should use the best
evidence available, be explicit about data limitations and any
attempts to overcome these, and quantify as fully as possible how
the limitations of the data are reﬂected in the uncertainty in the
results of the analysis.”
Pharmacoeconomic Guidelines 1033
With respect to utility values, the NICE guidelines state that:
“The valuation of changes in HRQL reported by patients should
be based on public preferences, elicited using a choice-based
method in a representative sample of the UK population” and
“The EQ-5D is the preferred measure of HRQL in adults. When
EQ-5D data are not available or are inappropriate for the
condition or effects of treatment, the valuation methods should
be fully described and comparable to those used for the EQ-5D.”
For example, “methods can be used to estimate EQ-5D utility
data by mapping (also known as “cross-walking”) EQ-5D utility
data from other HRQL measures included in the relevant clinical
trial(s).” Finally, “[t]he EQ-5D may not be an appropriate
measure of health-related utility in all circumstances. When an
alternative measure is preferred, those submitting analysis should
provide reasons, supported by empirical data on the properties of
the instrument used.”
The results of the analysis are presented in Table 2. It should
be noted that some of these results are based on a single tech-
nology assessment submitted by the manufacturer and reviewed
by an expert review group (ERG) that makes comments to the
Appraisal Committee. In other cases, appraisals are based both
on a manufacturer submission and a technology assessment pro-
duced by the independent group. In this section, we focus on
economic submissions prepared by manufacturers, plus any con-
cerns raised by the Committee, or the ERG. More detailed results
on all submissions are presented in Appendix 2 at: http://
www.ispor.org/Publications/value/ViHsupplementary/ViH13i8_
Drummond.asp.
With respect to utility values, it is clear that the vast
majority of submissions followed the NICE guidelines, either
using the EQ-5D instrument in UK patients, using the EQ-5D in
patients from other countries but then applying UK tariffs, or
using disease-speciﬁc instruments that were then mapped to
EQ-5D scores. There were only few cases (e.g., TA156, TA158,
TA166, and TA174) where different instruments and populations
were used, but this was generally justiﬁed. For example, in the
case of TA166, which considered cochlear implants for children
and adults with severe to profound deafness, it was stated that
the Health Utilities Index (HUI-3) was used as main source in all
the analyses because it was the only standard instrument which
includes items relating to functional limitations caused by
impaired hearing or speech. Only in the case of TA183, which
considered topotecan for the treatment of recurrent and stage
IVB cervical cancer, the use of Functional Assessment of Cancer
Therapy-General (FACT-G) appeared not to be justiﬁed and was
criticized by the ERG and the Committee.
More contrasting results were found for baseline risk.
Although the majority of submissions used local data, there
were several cases where epidemiological data, patients’ char-
acteristics, and/or disease progression were estimated on the
basis of populations from outside the UK. While in some cir-
cumstances the Appraisal Committee and /or the ERG consid-
ered these sources applicable and similar to the UK populations
or they were validated by UK experts (e.g., TA154, TA157,
TA159, TA163, TA170, TA174, TA178, TA182), there were
some cases where concerns were expressed by the Committee
Table 2 Source of data for baseline risk and health utilities in NICE technology assessments (July 2008–October 2009)
TA no Baseline risk Utility values
TA151 From UK database EQ-5D from UK study
TA152 From UK data audit SF-36, SF-12 and EQ-5D from UK patients
TA153 From literature: uncertainty on its application to UK population Standard gamble (SG) from a published study using UK tariffs
TA154 From a multinational trial (including UK). It was considered applicable
to UK (clinical specialists)
From published studies that used the EQ-5D generally conducted in
the UK
TA155 From literature: uncertainty on its application to UK population Different instruments and methods (HUI-3, time trade-off (TTO), SG).
UK values generally used
TA156 From UK epidemiological studies Canadian study that used the HUI-2
TA157 From 2 multinational trials that appear applicable to the UK EQ-5D and SG from UK populations and studies conducted in other
countries
TA158 Both UK data and published meta-analyses HUI-2 and 10-point Likert scale, not only from UK patients
TA159 From a multinational trial that appears applicable to the UK EQ-5D and SF-36 (UK tariffs)
TA160 Both UK data and epidemiological studies in several countries From a Swedish study that probably used the EQ-5D
TA161 Both UK data and epidemiological studies in several countries From a Swedish study that probably used the EQ-5D
TA162 From a trial not conducted in the UK: concerns on its applicability to
the UK populations
EQ-5D and VAS (UK tariffs)
TA163 From a trial conducted in France: values were validated by a panel of
UK specialists
EQ-5D from UK patients
TA164 Both UK studies and a trial not conducted in the UK with concerns
on its applicability.
EQ-5D from a study conducted in France, Germany and the UK.
TA165 From a UK registry From a UK study that used the EQ-5D
TA166 From UK databases and studies conducted in the UK HUI-3 from US and Canadian patients
TA167 From UK databases and studies conducted in the UK EQ-5D and SF-36 from UK patients
TA168 From studies conducted in the UK and UK registries EQ-5D and Harvard utility scores from UK and Dutch patients
TA169 From a multinational RCT, not clear if applicable to the UK population EQ-5D from a multinational trial using UK tariffs
TA170 From a trial relevant to the UK From published studies (EQ-5D preferred)
TA171 From trials with very few UK patients: concerns about its applicability
to the UK
EQ-5D from UK population
TA172 From a trial which appears relevant to the UK QLQ-30 converted to EQ-5D through an algorithm (UK tariffs)
TA173 Both UK data and other studies carried out in several countries SG and VAS from UK patients
TA174 From a trial which appears relevant to the UK Based on experts’ opinions
TA176 From 2 multinational trials validated by specialists EQ-5D and HUI from UK population
TA177 From a RCT which appears representative of the UK population DLQI values converted to EQ-5D scores (UK tariffs)
TA178 From a RCT relevant to the UK population EQ-5D from a RCT (UK tariffs)
TA179 From a multinational RCT, not clear if relevant to the UK EQ-5D from a UK study
TA180 From pooled values of 3 RCTs that appear relevant to the UK PASI and DLQI values mapped to EQ-5D scores
TA181 From a RCT with some differences compared to UK patients VAS and SG from UK population
TA182 From a RCT with comparable population to a UK registry EQ-5D from US population adjusted to UK values
TA183 From a multinational RCT, not clear if relevant to the UK FACT-G values from a trial
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about the relevance of data to the UK (e.g., TA153, TA155,
TA162, TA164, TA171, TA181). In many cases, data on
patients’ characteristics and/or natural progression of the
disease were taken from the pivotal trials on the company’s
product. Typically, these are multinational studies and may not
include the UK. (For example, data on disease progression is
sometimes taken from the placebo arm of an RCT). The appli-
cability of these data to UK patients depends on several factors,
including the similarity between populations, the comparability
of clinical practice (e.g., same usual care), or the disease area.
Sometimes, the data were discussed with experts who often
reached different conclusions about the applicability of the
data.
Methods Recommended for Addressing Issues
of Transferability
To examine the recommendations made by pharmacoeconomic
guidelines on methods to deal with the issue of transferability of
data, it is useful to make a distinction between two types of
economic evaluations: economic evaluations based on individual
patient data (IPD) and economic evaluations based on a
decision model. Different methods and issues exist for these two
situations.
In the case of studies based on a clinical trial, issues might
arise for adapting data to the country of interest from a clinical
trial performed in another country or a multinational study
with or without the inclusion of a substantial number of
patients from the reference country. Also, analysts might have to
choose whether clinical and/or economic data available from
multinational trials should be pooled or whether it is more
appropriate to take only data from the country of interest
(when represented in the trial). Different methods have been
suggested (e.g., statistical tests of homogeneity, ﬁxed-effect
models, and multilevel models) with different advantages and
disadvantages. The methods recommended to address the issue
of external validity of data obtained from clinical trials have
also been reviewed [2].
In the case of modeling, issues might arise about the
structural adaptation of the model among countries because
differences in comparators or patient populations might deter-
mine differences in practice patterns or natural history of
the disease. Nevertheless, the main issues for economic evalu-
ations based on decision models relate to methods used to
extract and synthesize data obtained from several sources, and
the methods to deal with the potential variability in the sources
of data.
Economic evaluations based on individual patient data. Most
guidelines do not make any recommendation on methods for
transferring data from clinical trials carried out in other countries
or multinational trials (with or without the inclusion of the
reference countries). Only ﬁve guidelines (Australia, Belgium,
Brazil, Canada, England and Wales) mention or suggest any
methods to deal with the issue of transferability of data from
economic evaluations based on clinical trials.
A common view is that clinical data from trials performed in
other settings are acceptable as the source of the relative treat-
ment effect, while absolute risk estimates or resource consump-
tion from these studies are difﬁcult to transfer. Similarly, the
guidelines generally suggest that clinical data from multinational
trials could be pooled, although this may not be the case for all
interventions, while economic data cannot be pooled because of
the potential differences in resource use and clinical practice
patterns between centers and countries. Only a few guidelines,
however, make explicit recommendations about how to deal
with these issues. Among these, the Brazilian guidelines suggest
conducting tests of homogeneity before pooling clinical data,
but do not recommend pooling resource-use data. The NICE
guidelines in England and Wales state that statistical pooling of
clinical data should be accompanied by an assessment of hetero-
geneity and that known clinical heterogeneity (for example,
because of patient characteristics, or intervention dose or fre-
quency) may be managed by judicious use of subgroup analyses
and meta-regression. Emphasis is also given in the Australian
guidelines to the need for assessing heterogeneity of patients, by
means of subgroup analysis or meta-regression, while the Cana-
dian guidelines are the only ones that recommend the use of
multilevel models (in addition to other methods such as multi-
variate regression models) to address the issue of clinical and
economic differences between centers and countries in a multi-
national study.
Economic evaluations based on decision models. The use of
decision models is often viewed by the guidelines as a method to
handle the variability and differences among settings. For
example, both the Dutch and Swedish guidelines state explicitly
that modeling is the key method for transferring data obtained
from other countries to the local context. Other guidelines also
say that the use of modeling should help to address the issue of
transferability among jurisdictions (mainly by means of sensitiv-
ity analyses).
The need for adapting the model structure to the local context
is explicitly mentioned only in the Belgian and Spanish guide-
lines, where it is stated that adjustments to models may be
needed, especially when there are differences in practice patterns.
Nevertheless, most of the guidelines state that an external vali-
dation of the model should be conducted to conﬁrm that the
model structure adequately reﬂects the clinical patterns and the
underlying nature of the disease in the local context.
Study selection and methods to synthesize data are considered
important issues for appropriately populating decision models.
In general, it seems that the guidelines give more importance to
the quality of the studies used as the source of effectiveness data,
rather than to their speciﬁc setting. RCTs are generally preferred
as the source of clinical data, even when not conducted in the
reference country, although it is often stated that clinical esti-
mates need to be appropriate for the study question and target
population. Again, some of the most detailed guidelines (Canada,
United States, England and Wales) state that the preferred
method for incorporating estimates of treatment effectiveness is
to combine relative risk estimates from (international) clinical
trials with estimates of baseline risk from local epidemiological
or public health data.
When data from more than one trial are available, meta-
analysis is the preferred method for synthesizing clinical data.
Some guidelines (Australia, England and Wales) state that it is
fundamentally important to take account of the heterogeneity
among studies included in the meta-analysis, for example by
means of random-effect models or meta-regression. The NICE
guidelines also suggest that some studies included in the meta-
analysis could be excluded in a sensitivity analysis to assess the
impact of different sources of data on cost-effectiveness results.
The need for local sources of economic data to include in the
decision model is highlighted by most of the guidelines, often
recommending the use of expert opinion when no valid published
data are available. Finally, most guidelines state that the issue of
transferability between countries should be addressed by means
of sensitivity analyses.
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Discussion
There is considerable diversity among the 27 sets of guidelines
concerning issues of transferability of data and how to deal with
them. Nevertheless, several points do emerge.
First, estimates of relative (clinical) treatment effect are gen-
erally thought to be more transferable than most of the eco-
nomic data elements. Nevertheless, in most of the guidelines,
great emphasis is placed on the issue of external validity of data
obtained from clinical trials. Almost all the guidelines state that
there are important differences in patients and clinical out-
comes observed in RCTs versus real (local) practice (i.e., efﬁ-
cacy versus effectiveness) and these should be taken into
account in the economic analysis even when the trial is carried
out in the reference country. In particular, it is thought that
important differences often exist in terms of patient character-
istics, methods of selection, compliance with treatment regi-
mens, dosages, level of expertise of personnel, etc. In addition,
the time horizon and the end points used in clinical trials are
often inappropriate for economic evaluations. Some guidelines
encourage the use of economic models for transforming efﬁcacy
results into effectiveness parameters. As mentioned earlier,
however, these issues go far beyond that of transferability
across jurisdictions and would be relevant if one were consid-
ering the results of a trial-based economic evaluation conducted
in the local jurisdiction.
More generally, the views expressed in the guidelines suggest
a triage, with estimates of relative treatment effect being gener-
ally viewed as having high transferability, estimates of costs/unit
prices and baseline measures of clinical events viewed as having
low transferability and resource utilization and health state pref-
erences being in the middle ground. Nevertheless, few of the sets
of guidelines provide justiﬁcations for these judgments and few, if
any, are based on empirical investigation. The Good Research
Practices Task Force report reviewed some of the existing
research on economic data transferability, but clearly more is
needed, with the recommendations of national guidelines being
updated accordingly. For example, the Task Force felt that the
evidence on the transferability/nontransferability of health state
preference values was inconclusive. Nevertheless, recent study
casts considerable doubt on the generalizability of the utility
estimates for the EQ-5D [3,4].
Second, some guidelines are much more detailed than others.
A major deﬁciency of some guidelines is the failure to distinguish
between treatment effect and baseline risk when discussing the
transferability of clinical data because these two data elements
differ greatly in their level of generalizability. In discussing the
transferability of economic data, however, almost all the guide-
lines distinguish between estimates of resource utilization and
unit costs/prices.
Third, to a large extent, it appears that countries are more
liberal in their assessments of transferability where local data are
less readily available. The cost of conducting evaluations would
be greatly increased if local data had to be gathered in every
jurisdiction.
Fourth, many of the differences between jurisdictions appear
to be related to the publication date of the guidelines, or the level
of maturity of economic evaluation in the jurisdiction concerned.
The more recent the publication of the guidelines, or the more
mature the country in terms of its development of economic
evaluation, the greater the level of detail in the discussion of
transferability issues and the lower the likelihood that items of
data from elsewhere will be considered transferable.
Fifth, in an analysis of submissions to NICE in the UK, the
level of adherence to the guidelines by applicant companies and
by the Appraisal Committee was high. Nevertheless, it is
unclear whether this ﬁnding is generalizable to other settings
and further analysis would be required as, and when, more data
on appraisal processes in other jurisdictions become publicly
available
Finally, although transferability of data is viewed as being
important in all the sets of guidelines, very few methods are
proposed for dealing with issues of transferability. Where
methods are proposed, it is instructive to assess whether these are
in line with the recommendations made by the recent report of
the ISPOR Task Force on this topic. The main differences appear
in the methods for adapting estimates of treatment effect. Most
of the guidelines view estimates of relative treatment effect as
transferable. In contrast, the Task Force recommends that tests of
heterogeneity should be performed on both the clinical and eco-
nomic parameters before considering the data to be transferable
across jurisdictions. In multilocation trials, tests of heterogeneity
will typically be performed on the estimate of treatment effect as
part of the statistical analysis plan for the clinical trial. Never-
theless, the Task Force report notes that 1) such tests may be
underpowered to detect meaningful differences and that 2) for
economic analysis one might be interested in the level of hetero-
geneity in the estimate of cost-effectiveness, rather than the esti-
mate of effectiveness.
Therefore, the recommended approach for analyzing IPD
including economic data will often be to construct a multiple
regression model. Whether this is an option for a speciﬁc juris-
diction depends on data availability. If the IPD data are available,
multilevel models are often preferred because they recognize the
hierarchical structure of the data, which occurs because of
within-jurisdiction similarities in clinical practice patterns and
patient characteristics. When analyzing data from multilocation
studies involving study sites in several jurisdictions, these models
allow for lower level clustering (e.g., study sites, clinical centers
or physicians), as well as heterogeneity in treatment effect, to be
incorporated in the analysis. By extension, they provide a formal
means of estimating jurisdiction-speciﬁc measures of cost-
effectiveness through the calculation of random intercepts and
random slopes, also described as empirical Bayesian shrinkage
estimation [2].
The views expressed in the various national guidelines are
more similar to the Task Force recommendations on addressing
transferability issues through the use of decision-analytic models.
Nevertheless, the Task Force recommendations are both more
speciﬁc and more comprehensive than those typically found in
any of the various national guidelines.
Conclusions
A growing number of jurisdictions are using guidelines for the
economic evaluation of pharmaceuticals. The recommendations
in existing guidelines regarding the transferability of clinical and
economic data are quite diverse. There is a case for standardiza-
tion in dealing with transferability issues along the lines of the
recommendations by the recent ISPOR Good Practices Task
Force on Economic Data Transferability. One important step
would be to update guidelines more frequently because this
analysis suggested that the older guidelines were less detailed in
their discussion of transferability issues.
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